48
Participants
Start Date
April 30, 2009
Primary Completion Date
July 31, 2010
Study Completion Date
July 31, 2010
PF-00489791
tablet form, 1 mg, single dose (Day 1)
PF-00489791
tablet form, 2 mg, single dose (Day 1)
PF-00489791
tablet form, 4 mg, single dose (Day 1)
PF-00489791
tablet form, 10 mg, single dose (Day 1)
PF-00489791
tablet form, 20 mg, single dose (Day 1)
placebo
tablet form, single dose (Day 1)
sildenafil
tablet form, 20 mg, single dose (Day 1)
Allegheny General Hospital, Pittsburgh
Hospital Universitario 12 de Octubre, Madrid
Shands at University of Florida, Gainesville
Creighton University Medical Center, Omaha
Thoraxklinik am Universitaetsklinikum, Heidelberg
UT Southwestern Medical Center - Department of Internal Medicine Pulmonary, Dallas
UT Southwestern St. Paul Hospital, Dallas
Pulmonary Associates, PA, Phoenix
John C. Lincoln Hospital, North Mountain, Phoenix
Pulmonary Associates, PA, Phoenix
"Moscow Healthcare Institution City Clinical Hospital No. 57", Moscow
Institute of Cardiosurgery n.a. V.I.Burakovsky, Moscow
Lawson Health Research Institute, London
London Health Sciences Centre, London
Sir Mortimer B. Davis, Jewish General Hospital, Montreal
Department Of Cardiology, MediCiti Hospital,, Hyderabad
Department Of Cardiology, Sri Venkateswara Institute Of Medical Sciences, Tirupati
Bankers Heart Institute, Vadodara
Omega Hospital, Mangalore
Hospital General Universitari Vall D´Hebron, Barcelona
Hospital Clinic I Provincial, Barcelona
Universitetssjukhuset i Lund, Hjart- och Lungdivisionen, Lund
Norrlands Universitetssjukhus, Kliniskt Forsknings Centrum, Umeå
Akademiska Sjukhuset, Kardiologen 50F/Forskningsenheten, Uppsala
Universitaetsspittal Zuerich, Medizinische Klinik A, Zurich
Lead Sponsor
Pfizer
INDUSTRY